Clinical behavior and outcomes of BRCA-mutated breast cancer in young patients according to type of BRCA mutation and hormone receptor status: Results from an international cohort study

被引：0

作者：

Lambertini, Matteo ^{[1
]}

Ceppi, Marcello ^{[1
]}

Hamy, Anne-Sophie ^{[2
]}

Caron, Olivier ^{[3
]}

Poorvu, Philip D. ^{[4
]}

Carrasco, Estela ^{[5
]}

Grinshpun, Albert ^{[6
]}

Punie, Kevin ^{[7
]}

Rousset-Jablonski, Christine ^{[8
]}

Ferrari, Alberta ^{[9
]}

Paluch-Shimon, Shani ^{[10
]}

Toss, Angela ^{[11
]}

Senechal, Claire ^{[12
]}

Puglisi, Fabio ^{[13
]}

Pogoda, Katarzyna ^{[14
]}

Perez-Fidalgo, Jose Alejandro ^{[15
]}

De Marchis, Laura ^{[16
]}

Ponzone, Riccardo ^{[17
]}

Livraghi, Luca ^{[18
]}

Estevez-Diz, Maria Del Pilar ^{[19
]}

Villarreal-Garza, Cynthia ^{[20
]}

Dieci, Maria Vittoria ^{[21
]}

Clatot, Florian ^{[22
]}

Duhoux, Francois P. ^{[23
]}

Graffeo, Rossella ^{[24
]}

Teixeira, Luis ^{[25
]}

Cordoba, Octavi ^{[26
]}

Sonnenblick, Amir ^{[27
]}

Ferreira, Arlindo R. ^{[28
]}

Partridge, Ann H. ^{[4
]}

Di Meglio, Antonio ^{[3
]}

Saule, Claire ^{[29
]}

Peccatori, Fedro A. ^{[30
]}

Bruzzone, Marco ^{[1
]}

Del Mastro, Lucia ^{[1
]}

Ameye, Lieveke ^{[31
,32
]}

Balmana, Judith ^{[5
]}

Azim, Hatem A., Jr. ^{[33
]}

机构：

[1] Univ Genoa, IRCCS Osped Policlin San Martino, Genoa, Italy

[2] Inst Curie, Parisq, Italy

[3] Inst Gustave Roussy, Villejuif, France

[4] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA

[5] Hosp Univ Vall dHebron Barcelona Hosp Campus, Vall dHebron Inst Oncol VHIO, Barcelona, Spain

[6] Hadassah Hebrew Univ Med Ctr, Jerusalem, Israel

[7] Univ Hosp Leuven, Leuven Canc Inst, Leuven, Belgium

[8] Ctr Leon Berard, Lyon, France

[9] Univ Pavia, Fdn IRCCS Policlin San Matteo, Pavia, Italy

[10] Shaare Zedek Med Ctr, Jerusalem, Israel

[11] Azienda Osped Univ Policlin Modena, Modena, Italy

[12] Bergonie Inst, Bordeaux, France

[13] Ctr Riferimento Oncol Avano CRO IRCCS, Aviano, Italy

[14] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[15] INCLIVA Univ Hosp Valencia, Valencia, Spain

[16] Univ Roma La Sapienza, Rome, Italy

[17] FPO IRCCS, Candiolo Canc Inst, Candiolo, Italy

[18] ASST Papa Giovanni XXIII, Bergamo, Italy

[19] Univ Sao Paulo, Fac Med, Inst Canc Estado Sao Paulo, Sao Paulo, Brazil

[20] Tecnol Monterrey, Pital Zambrano Hell, San Pedro Garza Garcia, Mexico

[21] Univ Padua, Padua, Italy

[22] Ctr Henri Becquerel, Rouen, France

[23] UCLouvain, Clin Univ St Luc, Brussels, Belgium

[24] Oncol Inst Southern Switzerland, Bellinzona, Switzerland

[25] Univ Paris, St Louis Hosp, Paris, France

[26] Hosp Univ Son Espases, Palma De Mallorca, Spain

[27] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel

[28] Champalimaud Fdn, Champalimaud Clin Ctr, Lisbon, Portugal

[29] Inst Curie, Paris, France

[30] European Inst Oncol IRCCS, Milan, Italy

[31] Inst Jules Bordet, Brussels, Belgium

[32] Univ Libre Bruxelles ULB, Brussels, Belgium

[33] Tecnol Monterrey, Hosp Zambrano Hell, San Pedro Garza Garcia, Mexico

来源：

CANCER RESEARCH | 2021年 / 81卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PD10-06

引用

页数：2

共 50 条

[31] Reproductive factors and risk of contralateral breast cancer by BRCA1 and BRCA2 mutation status: results from the WECARE study
Poynter, Jenny N.
Langholz, Bryan
Largent, Joan
Mellemkjaer, Lene
Bernstein, Leslie
Malone, Kathleen E.
Lynch, Charles F.
Borg, Ake
Concannon, Patrick
Teraoka, Sharon N.
Xue, Shanyan
Diep, Anh T.
Torngren, Therese
Begg, Colin B.
Capanu, Marinela
Haile, Robert W.
Bernstein, Jonine L.
CANCER CAUSES & CONTROL, 2010, 21 (06) : 839 - 846
[32] Reproductive factors and risk of contralateral breast cancer by BRCA1 and BRCA2 mutation status: results from the WECARE study
Jenny N. Poynter
Bryan Langholz
Joan Largent
Lene Mellemkjær
Leslie Bernstein
Kathleen E. Malone
Charles F. Lynch
Åke Borg
Patrick Concannon
Sharon N. Teraoka
Shanyan Xue
Anh T. Diep
Therese Törngren
Colin B. Begg
Marinela Capanu
Robert W. Haile
Jonine L. Bernstein
Cancer Causes & Control, 2010, 21 : 839 - 846
[33] Niraparib Efficacy and Safety in Patients With BRCA-Mutated Ovarian Cancer: Results From Three Phase 3 Niraparib Trials
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (08) : 7 - 8
[34] Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ (R) study
Miller, Robert S.
Mokiou, Stella
Taylor, Aliki
Sun, Ping
Baria, Katherine
BREAST CANCER RESEARCH AND TREATMENT, 2022, 193 (01) : 83 - 94
[35] Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
Laura M. Spring
Hyo Han
Minetta C. Liu
Erika Hamilton
Hanna Irie
Cesar A. Santa-Maria
James Reeves
Peng Pan
Ming Shan
Yongqiang Tang
Julie R. Graham
Sebastien Hazard
Leif W. Ellisen
Steven J. Isakoff
Nature Cancer, 2022, 3 : 1138 - 1138
[36] Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD
Senkus-Konefka, E.
Domchek, S. M.
Im, S. A.
Xu, B.
Armstrong, A.
Masuda, N.
Delaloge, S.
Li, W.
Tung, N.
Conte, P.
Wu, W.
Goessl, C.
Runswick, S.
Robson, M.
EUROPEAN JOURNAL OF CANCER, 2018, 92 : S19 - S20
[37] Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study
Copson, Ellen R.
Maishman, Tom C.
Tapper, Will J.
Cutress, Ramsey I.
Greville-Heygate, Stephanie
Altman, Douglas G.
Eccles, Bryony
Gerty, Sue
Durcan, Lorraine T.
Jones, Louise
Evans, D. Gareth
Thompson, Alastair M.
Pharoah, Paul
Easton, Douglas F.
Dunning, Alison M.
Hanby, Andrew
Lakhani, Sunil
Eeles, Ros
Gilbert, Fiona J.
Hamed, Hisham
Hodgson, Shirley
Simmonds, Peter
Stanton, Louise
Ecclest, Diana M.
LANCET ONCOLOGY, 2018, 19 (02): : 169 - 180
[38] Survival Outcomes and Efficacy of Platinum in Early Breast Cancer Patients with Germline BRCA1 or BRCA2 Mutation: A Multicenter Retrospective Cohort Study
Chen, Xi
Qian, Xiaoyan
Xiao, Min
Zhang, Pin
BREAST CANCER-TARGETS AND THERAPY, 2023, 15 : 671 - 682
[39] Niraparib efficacy and safety in patients with BRCA-mutated (BRCAm) ovarian cancer: Results from three phase 3 niraparib trials
Banerjee, Ashish
Gonzalez-Martin, Antonio
Matulonis, Ursula
Korach, Jacob
Mirza, Mansoor R.
Moore, Kathleen
Gupta, Divya
Lechpammer, Stanislav
Monk, Bradley J.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 116 - 117
[40] Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial
Hurvitz, Sara A.
Gocalves, Anthony
Rugo, Hope S.
Lee, Yung-Hun
Fehrenbacher, Louis
Mina, Lida A.
Diab, Sami
Blum, Joanne L.
Chakrabarti, Jayeta
Elmeliegy, Mohamed
DeAnnuntis, Liza
Gauthier, Eric
Czibere, Akos
Tudor, Iulia Cristina
Quek, Ruben G. W.
Litton, Jennifer K.
Ettl, Johannes
ONCOLOGIST, 2020, 25 (03): : E439 - E450

← 1 2 3 4 5 →